Freezing out tumors: new hope for rare desmoid disease
NCT ID NCT02476305
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a freezing technique called cryoablation on 50 adults with desmoid tumors that had grown despite medical treatment. The goal was to stop tumor growth and ease symptoms without surgery. Researchers used MRI to guide the freezing and check results one year later.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- cryoablation (freezing therapy using cryoprobes)
- What this could lead to
- If successful, cryoablation could provide a non-surgical way to control desmoid tumors, reduce pain, and improve quality of life for patients who have not responded to other treatments.
- What could go wrong
- This is a small, early-phase study (50 participants) with no control group. The procedure may not work for all tumor locations, and there is a risk of incomplete destruction or recurrence.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
50 people
The number who actually took part.
- Started
-
May 2015
- Finished
-
Nov 2017
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Extra-abdominal desmoid tumor (confirmed by prior biopsy) * 18 years of age or older * Tumor deemed accessible for cryoablation procedure by the operator in the investigator center * At least one measurable lesion (RECIST v1.1) using MRI (gadolinium injection mandatory) * 90 % of destruction of the tumor achievable in one procedure of cryoablation with a possible second cryoablation procedure (if a complete treatment must be achieved). * Progressive disease under standard treatment (after at least two lines of adequate medical therapy, including tamoxifen, non-steroid anti-inflamatory or chemotherapy), with presence of functional symptoms and/or pain The definition of progressing tumors also involves patients with RECIST stable disease, but with persistent functional disability or tumor-induced pain not controlled by adequate pain medication including narcotics. * Unresectable tumor or tumor amenable only to mutilating surgery, deemed inappropriate, and discussed in multidisciplinary meeting (RCP) * ECOG performance status 0-2 * Biological and hematological parameters: * neutrophils 1,5.109/L * platelet count 100.109/L * No significant hemostatic abnormalities * Subject affiliated to social security * Signed informed consent Exclusion Criteria: * Any contra-indication for the procedure as stated by the radiologist in terms of tumor size, proximity to neural/vascular structures making the procedure at unacceptable risk * Impaired hemostasis, that may interfere with the conduct of the cryoablation * Concurrent participation in other experimental studies that could affect endpoints of this study * Contraindication to any form of sedation * Contraindication to MRI or gadolinium injection (proven allergy, subject with impaired renal function (defined by a creatinine clearance below 30 ml/min by MDRD formula)) * Psychiatric disorders and adults under guardianship * Pregnancy or breastfeeding * Patients under judicial protection
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Desmoid tumors are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Service d'Imagerie Interventionnelle
Strasbourg, Alsace, 67091, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.